DEVELOPMENT JOURNEY TO REPLACE NEURONS LOST TO ALZHEIMER’S DISEASE WITH NEURAL PRECURSOR CELLS DERIVED FROM SKIN CELLS
With
Professor Michael Valenzuela,
Founder and Chief Scientific Officer,
Skin2Neuron
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Sydney | June 2026
Professor Michael Valenzuela is a science opinion leader, innovator and creative thinker with a career-long commitment to the prevention and treatment of dementia.
He studied psychology at the University of New South Wales (UNSW) before completing a PhD on Cognitive Reserve. This work was recognised by one of the nation’s top awards, the Australian Museum Eureka Prize for Medical Research.
Following that he completed graduate medicine and medical training at the Prince of Wales Hospital. In 2012, he established the Regenerative Neuroscience Group at the University of Sydney, and in 2017 became the university’s first Professor of Regenerative Medicine.
Professor Valenzuela’s group discovered a new cell type with potential for regenerative medicine, a rare neural precursor cell found deep within the human hair follicle. He is the main inventor on several related patents and is the Founder and Chief Scientific Officer of Skin2Neuron – a biotech company developing the first neurorestorative cell therapy for Alzheimer’s disease based on this work.
Between 2019-2021 he was employed as a senior advisor to the WHO in one of its flagship Decade of Healthy Ageing initiatives. He also joined the Centre for Healthy Brain Ageing at UNSW as Visiting Professor and played a leading role in the design and successful completion of the Maintain Your Brain – the world’s largest dementia prevention trial that found it is possible to delay cognitive decline in older at-risk people by about 1-year.
Professor Valenzuela is a frequent media commentator and author of the popular science book Maintain Your Brain.
Source: Supplied
-
Bringing the circular healthcare economy to life
Professor Dr.Geoff Sussman holds a position in the Faculty of Medicine, Nursing and Health Sciences Monash University, and is the Adjunct Professor of Wound Care He is a wound consultant at the Wound Clinic Austin Hospital.
-
Value of MedTech Report brings Industry and Government together
In June 2023 the Medical Technology Association of Australia (MTAA) launched The Value of MedTech Report – a major study quantifying the difference the MedTech industry makes to the lives of Australian patients, the healthcare system and the Australian economy.
Australian Health Journal spoke with MTAA CEO, Ian Burgess and MTAA Policy Manager, Pravin Siriwardena about the report and its key findings.
-
Global MedTech company brings device reprocessing plant to Australia
Cardinal Health is global medical products manufacturer and leading provider of single-use device reprocessing services in the U.S. In Australia and New Zealand, as one of the largest suppliers of medical devices, announced on 23 May 2024 that it will be opening a single-use medical device reprocessing facility in Australia – its first reprocessing facility outside the United States.
On 18 March 2025 at the Health Innovation Living Lab at the John Hunter Hospital, a further announcement was made, on the chosen single-use medical device remanufacturing facility in Beresfield, Newcastle, set to commence operation late 2025, supported by the NSW Department of Primary Industries and Regional Development.
